Growing data suggests that JAK inhibitors may be more effective than TNF inhibitors for the treatment of RA. The Great Debate asked, is it time to revisit the ACR guideline?

The 2020 version of the Year in Review included looks at positive lupus trial results and high-dimensional profiling by single-cell RNA-sequencing.

Better understanding of the interface between the mechanisms that define infectious disease and rheumatology is contributing to progress toward COVID-19 treatments and a vaccine, according to Eric Rubin, MD.

Support and encouragement to get involved can change a patient’s trajectory, says this year’s ARP Keynote lecturer.

“We’re hoping to tackle some challenging areas in day-to-day practice that don’t always fit in the traditional talks that are given at the meeting,” said Jason Kolfenbach, MD.

Clinicians need knowledge in this area because patients will come to them with questions and interest in these treatments, said Neha Shah, MD. Patients want additional things that they can do to help their autoimmune process besides prescription medications.

Biomarkers have the potential to turn that tide through earlier identification of need for intervention, earlier identification and follow-up of specific organ involvement, better measuring of disease activity, and increased ability to predict disease severity.

New for ACR Convergence 2020, the Down & Dirty 30 sessions will present rheumatology professionals a high-level overview of four of the field’s most important topics.